We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.35%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.46B
AUM Growth
-$2.68M
Cap. Flow
-$106M
Cap. Flow %
-1.64%
Top 10 Hldgs %
39.36%
Holding
145
New
22
Increased
28
Reduced
21
Closed
17

Top Buys

Rank Stock Value
1
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$201M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$91.6M
3
QURE icon
uniQure
QURE
+$57.2M
4
NTRA icon
Natera
NTRA
+$47.4M
5
ATNX
Athenex, Inc. Common Stock
ATNX
+$47.3M

Top Sells

Rank Stock Value
1
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$272M
2
GH icon
Guardant Health
GH
+$118M
3
VTRS icon
Viatris
VTRS
+$77.1M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$64M
5
HUM icon
Humana
HUM
+$55.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.58%
2 Financials 1.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$443M 6.86%
3,846,673
-124,000
-3% -$14.8M
TCDA
2
DELISTED
Tricida, Inc. Common Stock
TCDA
$439M 6.79%
11,114,280
+225,000
+2% +$7.91M
BSX icon
3
Boston Scientific
BSX
$68.5B
$290M 4.49%
6,752,500
+962,100
+17% +$37M
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$252M 3.91%
1,926,085
-31,115
-2% -$4.01M
ALEC icon
5
Alector
ALEC
$169M
$250M 3.88%
13,182,329
– –
MRK icon
6
Merck
MRK
$326B
$216M 3.34%
2,693,465
– –
PRVL
7
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$182M 2.83%
+13,822,463
New +$201M
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$124B
$178M 2.76%
973,300
+18,000
+2% +$3.15M
NBIX icon
9
Neurocrine Biosciences
NBIX
$18.4B
$155M 2.4%
1,833,200
– –
IOVA icon
10
Iovance Biotherapeutics
IOVA
$2.1B
$136M 2.11%
5,548,326
– –
TMO icon
11
Thermo Fisher Scientific
TMO
$214B
$136M 2.1%
462,800
+15,500
+3% +$4.27M
EW icon
12
Edwards Lifesciences
EW
$48.2B
$132M 2.05%
2,145,000
– –
SRPT icon
13
Sarepta Therapeutics
SRPT
$1.63B
$126M 1.95%
828,400
– –
WMGI
14
DELISTED
Wright Medical Group Inc
WMGI
$125M 1.93%
4,187,799
– –
ISRG icon
15
Intuitive Surgical
ISRG
$130B
$110M 1.71%
630,900
– –
TPTX
16
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$104M 1.62%
+2,567,550
New +$91.6M
ELV icon
17
Elevance Health
ELV
$83.7B
$102M 1.58%
361,600
+36,400
+11% +$9.94M
BHC icon
18
Bausch Health
BHC
$1.69B
$94.3M 1.46%
3,740,700
– –
PTCT icon
19
PTC Therapeutics
PTCT
$6.25B
$94M 1.46%
2,089,700
+570,000
+38% +$22.5M
INSP icon
20
Inspire Medical Systems
INSP
$1.5B
$89.2M 1.38%
1,471,000
– –
NTRA icon
21
Natera
NTRA
$36.1B
$88.9M 1.38%
3,224,328
+2,146,742
+199% +$47.4M
LOGC
22
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$84.1M 1.3%
6,466,783
– –
EXEL icon
23
Exelixis
EXEL
$14.2B
$83.6M 1.3%
3,912,900
+1,111,000
+40% +$23.3M
AVDR
24
DELISTED
Avedro, Inc Common Stock
AVDR
$83.3M 1.29%
4,240,128
– –
DCPH
25
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$81.6M 1.26%
3,618,171
– –
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2019 Portfolio in Review

As of Q2 2019, OrbiMed held 145 positions worth $6.46B, down 0.04% from $6.46B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

OrbiMed's Q2 2019 filing shows 22 new, 28 increased, 21 reduced and 17 closed positions. Its largest new stake was Prevail Therapeutics Inc. Common Stock: 13,822,463 shares worth $182M. The largest sale was Clementia Pharmaceuticals Inc., an estimated $272M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q2 2019 buy was Prevail Therapeutics Inc. Common Stock: 13,822,463 shares worth $182M.
  • OrbiMed added most to Natera in Q2 2019, an estimated $47.4M increase.
  • OrbiMed's biggest Q2 2019 reduction was Viatris, cutting an estimated $77.1M.
  • OrbiMed fully exited Clementia Pharmaceuticals Inc. in Q2 2019, selling an estimated $272M.
  • OrbiMed's ten largest holdings make up 39% of its $6.46B portfolio in Q2 2019.
  • OrbiMed opened 22 new positions and closed 17 in Q2 2019.
  • OrbiMed's portfolio value fell 0.04% quarter-over-quarter to $6.46B.

Based on OrbiMed's 13F filing for Q2 2019, filed 14 Aug 2019.